- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07409428
Uno studio di Fase III di HMPL-760 in combinazione con R-GemOx rispetto a placebo in combinazione con R-GemOx nel DLBCL recidivato/refrattario
Uno Studio di Fase III Randomizzato, in Doppio Cieco, Controllato Positivo per Valutare l'Efficacia, la Sicurezza e la Farmacocinetica di HMPL-760 in Combinazione con R-GemOx Rispetto al Placebo in Combinazione con R-GemOx in Pazienti con Linfoma Diffuso a Grandi Cellule B (DLBCL) Recidivato/Refrattario
This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.
The target population of this study includes patients with DLBCL who are relapsed or refractory.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 3
Contatti e Sedi
Contatto studio
- Nome: Dongmei Chen, CPL
- Numero di telefono: 86-21-20671794
- Email: dongmeic@hutch-med.com
Luoghi di studio
-
-
-
Baoding, Cina
- Reclutamento
- Baoding NO.1 Central Hospital
-
Contatto:
- Haiying Yao
- Numero di telefono: 18617789030
- Email: haiyingyaobd@163.com
-
Investigatore principale:
- Haiying Yao
-
Beijing, Cina
- Reclutamento
- Beijing GoBroad Hospital
-
Investigatore principale:
- Kai Hu
-
Contatto:
- Kai Hu
- Numero di telefono: 15010390336
- Email: HK13610956245@163.com
-
Beijing, Cina
- Reclutamento
- BEIJING TONGREN HOSPITAL, Capital Medical University
-
Investigatore principale:
- Liang Wang
-
Contatto:
- Liang Wang
- Numero di telefono: 15001108693
- Email: wangliangtrhos@126.com
-
Bengbu, Cina
- Reclutamento
- The First Affiliated Hospital of Bengbu Medical College
-
Contatto:
- Yanli Yang
- Numero di telefono: 13855249678
- Email: Yangyanli0702@126.com
-
Investigatore principale:
- Yanli Yang
-
Changchun, Cina
- Reclutamento
- The First Hospital of Jilin University
-
Investigatore principale:
- Ou Bai
-
Contatto:
- Ou Bai
- Numero di telefono: 13039046656
- Email: lbl2054@163.com
-
Changsha, Cina
- Reclutamento
- Hunan Cancer Hospital
-
Investigatore principale:
- Hui Zhou
-
Contatto:
- Hui Zhou
- Numero di telefono: 13975879796
- Email: zhouhui9403@126.com
-
Changsha, Cina
- Reclutamento
- The Second Xiangya Hospital of Central South University
-
Investigatore principale:
- Hongling Peng
-
Contatto:
- Hongling Peng
- Numero di telefono: 18900766137
- Email: Penghongling@aliyun.com
-
Changsha, Cina
- Reclutamento
- People's Hospital of Hunan Province
-
Contatto:
- Can Liu
- Numero di telefono: 137 8728 5260
- Email: 617170469@qq.com
-
Investigatore principale:
- Can Liu
-
Chengdu, Cina
- Reclutamento
- West China Hospital of Sichuan University
-
Investigatore principale:
- Liqun Zou
-
Contatto:
- Liqun Zou
- Numero di telefono: 18980601027
- Email: Clinical_Zou@163.com
-
Chengdu, Cina
- Reclutamento
- Sichuan Provincial People's Hospital
-
Contatto:
- Xiaobing Huang
- Numero di telefono: 18981838236
- Email: hxb_trial@163.com
-
Investigatore principale:
- Xiaobing Huang
-
Chongqing, Cina
- Reclutamento
- The First Affiliated Hospital of Chongqing Medical University
-
Investigatore principale:
- Xin Wang
-
Contatto:
- Xin Wang
- Email: 925170788@qq.com
-
Chongqing, Cina
- Reclutamento
- Chongqing University Cancer Hospital
-
Investigatore principale:
- Yao Liu
-
Contatto:
- Yao Liu
- Email: liuyao101709@163.com
-
Fujian, Cina
- Reclutamento
- Quanzhou First Hospital.Fujian
-
Contatto:
- Xiongpeng Zhu
- Numero di telefono: 13805998581
- Email: xiongpengzhu@163.com
-
Investigatore principale:
- Xiongpeng Zhu
-
Fuzhou, Cina
- Reclutamento
- Fujian Medical University Union Hospital
-
Investigatore principale:
- Jianzhen Shen
-
Contatto:
- Jianzhen Shen
- Numero di telefono: 138 0955 2722
- Email: doctorsjz@163.com
-
Guangzhou, Cina
- Reclutamento
- Sun Yat-sen University Cancer Center
-
Investigatore principale:
- Zhiming Li
-
Contatto:
- Zhiming Li
- Numero di telefono: 13719189172
- Email: lzmsysu@163.com
-
Guangzhou, Cina
- Reclutamento
- Guangdong Provincial People's Hospital
-
Contatto:
- Xiaojuan Wei
- Numero di telefono: 86 13560097145
- Email: jxw919@hotmail.com
-
Investigatore principale:
- Xiaojuan Wei
-
Guangzhou, Cina
- Reclutamento
- ZhuJiang Hospital of Southern Medical University(The Second Clinical Medical College)
-
Investigatore principale:
- Yuhua Li
-
Contatto:
- Yuhua Li
- Numero di telefono: 13533706656
- Email: liyuhua2011gz@163.com
-
Guiyang, Cina
- Reclutamento
- The Affiliated Hospital of Guizhou Medical University
-
Investigatore principale:
- Yan Zhang
-
Contatto:
- Yan Zhang
- Numero di telefono: 86 18984155172
- Email: Zhangyan20010802@sina.com
-
Hangzhou, Cina
- Reclutamento
- Zhejiang Cancer Hospital
-
Investigatore principale:
- Haiyan Yang
-
Contatto:
- Haiyan Yang
- Email: 2054451461@qq.com
-
Hangzhou, Cina
- Reclutamento
- The First Affiliated Hospital, Zhejiang University
-
Investigatore principale:
- Zhen Cai
-
Contatto:
- Zhen Cai
- Numero di telefono: 13857190311
- Email: czclinicaltrial@163.com
-
Harbin, Cina
- Reclutamento
- Harbin Medical University Cancer Hospital
-
Contatto:
- Qingyuan Zhang
- Numero di telefono: 13313612989
- Email: sy86298276@163.com
-
Investigatore principale:
- Qingyuan Zhang
-
Hefei, Cina
- Reclutamento
- The Second Affiliated Hospital of Anhui Medical University
-
Contatto:
- Zhimin Zhai
- Numero di telefono: 13855147434
- Email: zzzm889@163.com
-
Investigatore principale:
- Zhimin Zhai
-
Jinan, Cina
- Reclutamento
- Qilu Hospital of Shandong University
-
Contatto:
- Shuqian Xu
- Numero di telefono: 18560087013
- Email: yoyoshuqian@126.com
-
Investigatore principale:
- Shuqian Xu
-
Jinan, Cina
- Reclutamento
- Shandong Cancer Hospital & Institute
-
Investigatore principale:
- Zengjun Li
-
Contatto:
- Zengjun Li
- Numero di telefono: 15735178591
- Email: zengjunli@163.com
-
Kunming, Cina
- Non ancora reclutamento
- The First Affiliated Hospital of Kunming Medical University
-
Contatto:
- Mingxia Shi
- Numero di telefono: 86 138 8806 0581
- Email: shmxia2002@sina.com
-
Investigatore principale:
- Mingxia Shi
-
Nanchang, Cina
- Reclutamento
- Jiangxi Cancer Hospital
-
Investigatore principale:
- Yan Huang
-
Contatto:
- Yan Huang
- Email: 29265061@qq.com
-
Nanjing, Cina
- Reclutamento
- Jiangsu Cancer Hospital
-
Investigatore principale:
- Yan Zhang
-
Contatto:
- Yan Zhang
- Numero di telefono: 13914712395
- Email: zhangyan1106@njmu.edu.cn
-
Nanjing, Cina
- Reclutamento
- Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
-
Contatto:
- Jingyan Xu
- Numero di telefono: 86 13951969610
- Email: xjy1967@sina.com
-
Investigatore principale:
- Jingyan Xu
-
Nanning, Cina
- Reclutamento
- The First Affiliated Hospital of Guangxi Medical University
-
Investigatore principale:
- Zhigang Peng
-
Contatto:
- Zhigang Peng
- Email: 2557382235@qq.com
-
Qingdao, Cina
- Reclutamento
- The Affiliated Hospital of Qingdao University
-
Contatto:
- Xia Zhao
- Numero di telefono: 18661803088
- Email: Zhaoxia@qdu.edu.cn
-
Investigatore principale:
- Xia Zhao
-
Shanghai, Cina
- Reclutamento
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine
-
Investigatore principale:
- Weili Zhao
-
Contatto:
- Weili Zhao
- Numero di telefono: 86 13512112076
- Email: zwl_trial@163.com
-
Shanghai, Cina
- Reclutamento
- Tongji Hospital of Tongji University
-
Contatto:
- Ping Li
- Numero di telefono: 13564181131
- Email: lilyforever76@126.com
-
Investigatore principale:
- Ping Li
-
Shanghai, Cina
- Non ancora reclutamento
- Tong Ren Hospital Shanghai Jiao Tong University School Of Medicine
-
Investigatore principale:
- Ligen Liu
-
Contatto:
- Ligen Liu
- Numero di telefono: 86 18017337037
- Email: llg3532@shtrhospital.com
-
Shenyang, Cina
- Reclutamento
- Shengjing Hospital of China Medical University
-
Investigatore principale:
- Wei Yang
-
Contatto:
- Wei Yang
- Numero di telefono: 18940251012
- Email: sjyangw@163.com
-
Shenzhen, Cina
- Reclutamento
- Shenzhen people's hospital
-
Investigatore principale:
- Jihao Zhou
-
Contatto:
- Jihao Zhou
- Numero di telefono: 86 18718678693
- Email: zhoujihao@aliyun.com
-
Taiyuan, Cina
- Reclutamento
- Shanxi Provincial Cancer Hospital
-
Investigatore principale:
- Liping Su
-
Contatto:
- Liping Su
- Numero di telefono: 13835158122
- Email: slpsy2022@163.com
-
Tangshan, Cina
- Reclutamento
- North China University of Science and Technology Affiliated Hospital
-
Contatto:
- Zhenyu Yan
- Numero di telefono: 15931508262
- Email: hbyzy2011@163.com
-
Investigatore principale:
- Zhenyu Yan
-
Tianjin, Cina
- Reclutamento
- Tianjin Medical University Cancer Institute & Hospital
-
Investigatore principale:
- Zhengzi Qian
-
Contatto:
- Zhengzi Qian
- Numero di telefono: 13702031222
- Email: qzz@163.com
-
Tianjin, Cina
- Reclutamento
- Tianjin People's Hospital
-
Contatto:
- Xingli Zhao
- Numero di telefono: 13752255454
- Email: insectzhao@163.com
-
Investigatore principale:
- Xingli Zhao
-
Tianjin, Cina
- Reclutamento
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
-
Investigatore principale:
- Dehui Zou
-
Contatto:
- Dehui Zou
- Numero di telefono: 13602100955
- Email: zoudehui@ihcams.ac.cn
-
Wenzhou, Cina
- Reclutamento
- The First Affiliated Hospital of WMU
-
Contatto:
- Songfu Jiang
- Numero di telefono: 86 15305770033
- Email: jiangsongfu@189.cn
-
Investigatore principale:
- Songfu Jiang
-
Wuhan, Cina
- Reclutamento
- Hubei Cancer Hospital
-
Investigatore principale:
- Huijing Wu
-
Contatto:
- Huijing Wu
- Email: 3269614878@qq.com
-
Wuhan, Cina
- Reclutamento
- Wuhan Union Hospital of China
-
Investigatore principale:
- Liling Zhang
-
Contatto:
- Liling Zhang
- Numero di telefono: 15871725926
- Email: lily1228@sina.com
-
Xi'an, Cina
- Reclutamento
- The First Affiliated Hospital of Xi'an Jiaotong University
-
Investigatore principale:
- Pengcheng He
-
Contatto:
- Pengcheng He
- Numero di telefono: 18991232609
- Email: hepc_gcp@163.com
-
Xi'an, Cina
- Reclutamento
- The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal)
-
Investigatore principale:
- Jie Liu
-
Contatto:
- Jie Liu
- Numero di telefono: 86 18092662371
- Email: lieujie@163.com
-
Xiamen, Cina
- Non ancora reclutamento
- The First Affiliated Hospital of Xiamen University
-
Investigatore principale:
- Bing Xu
-
Contatto:
- Bing Xu
- Numero di telefono: 86 18750918842
- Email: xubingzhangjian@126.com
-
Xuzhou, Cina
- Reclutamento
- The Affiliated Hospital of Xuzhou Medical University
-
Contatto:
- Wei Sang
- Numero di telefono: 86 13645207648
- Email: 13645207648@126.com
-
Investigatore principale:
- Wei Sang
-
Zhengzhou, Cina
- Reclutamento
- Henan Cancer Hospital
-
Investigatore principale:
- Keshu Zhou
-
Contatto:
- Keshu Zhou
- Numero di telefono: 13674902391
- Email: dr_zkshu23810@163.com
-
Zhengzhou, Cina
- Reclutamento
- The First Affiliated Hospital of Zhengzhou University
-
Contatto:
- Xudong Zhang
- Numero di telefono: 13633825183
- Email: feverxxd@126.com
-
Investigatore principale:
- Xudong Zhang
-
Ürümqi, Cina
- Reclutamento
- People's Hospital of Xinjiang Uygur Autonomous Region
-
Investigatore principale:
- Yan Li
-
Contatto:
- Yan Li
- Numero di telefono: 86 13639935315
- Email: liyan232917@139.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Cina
- Reclutamento
- Fudan University Shanghai Cancer Center
-
Contatto:
- Fangfang Lv
- Numero di telefono: 18017312613
- Email: Lvff80@163.com
-
Investigatore principale:
- Fangfang Lv
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Sign the ICF and be able to follow the requirements of study protocol;
- Age ≥18 years;
- ECOG performance status score between 0 and 2;
- Histopathologically confirmed diagnosis of DLBCL;
- The investigator judges that the patient's current condition requires further treatment;
- Patients should have at least one bi-dimensionally measurable lesion;
- Expected survival is more than 12 weeks;
Exclusion Criteria:
- Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
- Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
- Organ insufficiency;
- Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
- History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
- Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
- The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);
- Clinically significant active infection;
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: The experimental group
Patients will receive HMPL-760 once daily (QD) orally in combination with R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle. |
Patients will receive HMPL-760 once daily (QD) orally. R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.
Altri nomi:
|
|
Comparatore placebo: The control group
Placebo QD at the same dose as HMPL-760 in the experimental group will be given in the control group, and the combination therapy is the same as in the experimental group. |
R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.
Altri nomi:
Patients will receive HMPL-760 placebo once daily (QD) orally. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression-free survival (PFS)
Lasso di tempo: Up to approximately two years
|
Investigator-assessed progression-free survival (PFS) Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). PFS is defined as the time from randomization to PD or death due to any cause, whichever occurs first. |
Up to approximately two years
|
|
End of treatment (EOT)
Lasso di tempo: Up to approximately two years
|
Tumor assessment data will continue to be collected. Tumor assessment data collected after end of treatment (EOT) will be used. Tumor assessment data collected during the study and after EOT will be included in the PFS analysis (treatment policy strategy). |
Up to approximately two years
|
|
Systemic antitumor therapy
Lasso di tempo: Up to approximately two years
|
Use of other systemic antitumor therapy before PD or death (in the absence of PD):Tumor assessment after use of other systemic antitumor therapy will not be included in the analysis. For patients using other anti-tumor therapy before PD or death (in absence of PD), PFS will be censored at the last evaluable tumor assessment before the use of other systematic anti-tumor therapy (hypothetical strategy). |
Up to approximately two years
|
|
Overall survival (OS)
Lasso di tempo: Up to approximately two years
|
OS is defined as the time from randomization to death due to any cause. |
Up to approximately two years
|
|
systematic anti-tumor therapy
Lasso di tempo: Up to approximately two years
|
OS data will continue to be collected after the other systematic anti-tumor therapy, and the OS data collected before and after other systematic anti-tumor therapy will be included in analysis (treatment policy strategy). |
Up to approximately two years
|
|
Premature withdrawal from study treatment
Lasso di tempo: Up to approximately two years
|
OS data will continue to be collected after the patient's premature withdrawal from study treatment, and the OS data collected during the study treatment and after EOT will be included in analysis (treatment policy strategy). |
Up to approximately two years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Independent review committee (IRC)-assessed PFS
Lasso di tempo: Up to approximately two years
|
Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). |
Up to approximately two years
|
|
IRC- and investigator-assessed objective response rate (ORR)
Lasso di tempo: Up to approximately two years
|
Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR) |
Up to approximately two years
|
|
IRC- and investigator-assessed complete response rate (CRR)
Lasso di tempo: Up to approximately two years
|
Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR) |
Up to approximately two years
|
|
IRC- and investigator-assessed duration of response (DoR)
Lasso di tempo: Up to approximately two years
|
For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first |
Up to approximately two years
|
|
IRC- and investigator-assessed clinical benefit rate (CBR)
Lasso di tempo: Up to approximately two years
|
Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD) |
Up to approximately two years
|
|
IRC- and investigator-assessed time to response (TTR)
Lasso di tempo: Up to approximately two years
|
Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR) |
Up to approximately two years
|
|
Safety Endpoints
Lasso di tempo: Up to approximately two years
|
|
Up to approximately two years
|
|
PK characteristics of HMPL-760 in patients with R/R DLBCL when administered in combination with R-GemOx
Lasso di tempo: At the end of Cycle 4 (each cycle is 21 days)]
|
including but not limited to steady-state plasma concentrations of HMPL-760 pre-dose [trough concentrations (Ctrough)] and post-dose (C1h and C2h); If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis. If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis. |
At the end of Cycle 4 (each cycle is 21 days)]
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Biomarker assessment
Lasso di tempo: Up to approximately two years
|
Detect tumor driver gene mutations in tissue and blood samples, such as MYD88 and CD79B, etc, and explore the relationship between their mutation status and drug efficacy. |
Up to approximately two years
|
|
To explore the metabolite profile of HMPL-760 in combination with R-GemOx in tumor patients
Lasso di tempo: Up to approximately two years
|
Human metabolites of HMPL-760 when co-administered with R-GemOx |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Lasso di tempo: Up to approximately two years
|
maximum concentration in steady-state (Cmax,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Lasso di tempo: Up to approximately two years
|
time to maximum concentration in steady-state (Tmax,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Lasso di tempo: Up to approximately two years
|
Area Under the Curve at steady state refers to the area under the plasma concentration-time curve during a dosing interval at steady state conditions (AUC,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Lasso di tempo: Up to approximately two years
|
The rate at which the drug is eliminated from the body (CL/F) (if applicable ) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Lasso di tempo: Up to approximately two years
|
The distribution volume calculated based on the terminal elimination phase (Vz/F )(if applicable) |
Up to approximately two years
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Weili Zhao, Ruijin Hospital
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Malattie linfatiche
- Malattie linfoproliferative
- Disturbi immunoproliferativi
- Linfoma non Hodgkin
- Linfoma, cellule B
- Linfoma
- Malattie emiche e linfatiche
- Linfoma, a grandi cellule B, diffuso
- Aminoacidi, peptidi e proteine
- Proteine
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Terapie
- Rotte della somministrazione di droga
- Terapia farmacologica
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Complessi di coordinamento
- Deossictidina
- Citidina
- Nucleosidi di pirimidina
- Pirimidine
- Anticorpi, monoclonali, derivati da murina
- Oxaliplatino
- Rituximab
- Gemcitabina
- Iniezioni
Altri numeri di identificazione dello studio
- 2025-760-00CH1
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .